These epigenetic mechanisms in synovial sarcoma can be emphasized by an overexpression of EZH2 (enhancer of zeste homologue 2), which is described in poorly differentiated synovial sarcomas, and seems associated with a poorer prognosis (246). This evidence concerns the gene EZH2 and synovial sarcoma.